Skip to content

Advertisement

Articles

Page 1 of 5

  1. Content type: Research

    Second allogeneic hematopoietic stem cell transplant (HCT) remains as an option for disease relapse after initial HCT.

    Authors: Yun Fan, Andrew S. Artz, Koen van Besien, Wendy Stock, Richard A. Larson, Olatoyosi Odenike, Lucy A. Godley, Justin Kline, John M. Cunningham, James L. LaBelle, Michael R. Bishop and Hongtao Liu

    Citation: Experimental Hematology & Oncology 2019 8:1

    Published on:

  2. Content type: Research

    Senescence, a state of permanent cell cycle arrest, can be induced by DNA damage. This process, which was initially described in fibroblasts, is now recognized to occur in stem cells. It has been well characte...

    Authors: Stephen Capone, Anthony R. Colombo, Benjamin K. Johnson, Tim J. Triche Jr. and Giridharan Ramsingh

    Citation: Experimental Hematology & Oncology 2018 7:32

    Published on:

  3. Content type: Research

    The evolution of molecular studies in myeloproliferative neoplasms (MPN) has enlightened us the understanding of this complex disease consisting of polycythaemia vera (PV), essential thrombocythemia (ET) and p...

    Authors: Yee Yee Yap, Kian Boon Law, Jameela Sathar, Ngee Siang Lau, Ai Sim Goh, Teng Keat Chew, Soo Min Lim, Padmini Menon, Yong Khee Guan, Azlan Bin Husin, Lily Lee Lee Wong, Lee Ping Chew, Sinari Salleh, Kim Yen Goh, Kin Wah Leong, Sen Mui Tan…

    Citation: Experimental Hematology & Oncology 2018 7:31

    Published on:

  4. Content type: Review

    Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases...

    Authors: Hanxiao Xu, Ying Jiao, Shuang Qin, Weiheng Zhao, Qian Chu and Kongming Wu

    Citation: Experimental Hematology & Oncology 2018 7:30

    Published on:

  5. Content type: Research

    Refinement of risk-based treatment stratification by minimal residual disease (MRD) at different time points has improved outcomes of childhood acute lymphoblastic leukemia (ALL). In this prospective study we ...

    Authors: Wasil Jastaniah, Naglla Elimam, Khalid Abdalla, Aeshah A. AlAzmi, Aml M. Elgaml, Ahmad Alkassar, Mustafa Daghistani and Sami Felimban

    Citation: Experimental Hematology & Oncology 2018 7:29

    Published on:

  6. Content type: Review

    Immune checkpoint inhibitor induces tumor rejection by activated host immune system. The anti-tumor immune response consists of capture, presentation, recognition of neoantigen, as well as subsequent killing o...

    Authors: Ming Yi, Shuang Qin, Weiheng Zhao, Shengnan Yu, Qian Chu and Kongming Wu

    Citation: Experimental Hematology & Oncology 2018 7:28

    Published on:

  7. Content type: Research

    The monoclonal antibody daratumumab, approved for treating myeloma, targets CD38, a protein on myeloma and also on CD34+ hematopoietic progenitor cells. Because mobilized CD34+ cells are critical for stem cell...

    Authors: Xun Ma, Sandy W. Wong, Ping Zhou, Chakra P. Chaulagain, Parul Doshi, Andreas K. Klein, Kellie Sprague, Adin Kugelmass, Denis Toskic, Melissa Warner, Kenneth B. Miller, Lisa Lee, Cindy Varga and Raymond L. Comenzo

    Citation: Experimental Hematology & Oncology 2018 7:27

    Published on:

  8. Content type: Case report

    Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by neoplastic cells that are positive for CD123, CD4, BDCA2, and TCL1 and aberrant expression ...

    Authors: Kamal Chamoun, Sanam Loghavi, Naveen Pemmaraju, Marina Konopleva, Michael Kroll, Madeleine Nguyen-Cao, Marisa Hornbaker, Courtney D. DiNardo, Tapan Kadia, Jeffrey Jorgensen, Michael Andreeff, Shimin Hu and Christopher B. Benton

    Citation: Experimental Hematology & Oncology 2018 7:26

    Published on:

  9. Content type: Short report

    Immunotherapeutic protocols have focused on identification of stimuli that induce effective anti-leukemic immune responses. One potent immune stimulus is the encounter with allogeneic cells. Our group previous...

    Authors: Alejandro Pando, John L. Reagan, Martha Nevola and Loren D. Fast

    Citation: Experimental Hematology & Oncology 2018 7:25

    Published on:

  10. Content type: Review

    Estrogen is a steroid hormone that has critical roles in reproductive development, bone homeostasis, cardiovascular remodeling and brain functions. However, estrogen also promotes mammary, ovarian and endometr...

    Authors: Hui Hua, Hongying Zhang, Qingbin Kong and Yangfu Jiang

    Citation: Experimental Hematology & Oncology 2018 7:24

    Published on:

  11. Content type: Research

    Heparin-induced antibodies (HIA) are responsible for causing heparin-induced thrombocytopenia and thrombosis. Research has shown that the temporality of heparin-induced antibodies does not follow the classic i...

    Authors: Satish Maharaj, Simone Chang, Karan Seegobin, James Morales, Agnes Aysola, Fauzia Rana and Marwan Shaikh

    Citation: Experimental Hematology & Oncology 2018 7:23

    Published on:

  12. Content type: Research

    Chemotherapy-induced neutropenia is a common result of myelosuppressive chemotherapy treatment. Infections such as febrile neutropenia (FN) are sensitive to the duration of neutropenia as well as the depth of ...

    Authors: Kalpna Desai, Priya Misra, Sanyukta Kher and Nirmesh Shah

    Citation: Experimental Hematology & Oncology 2018 7:22

    Published on:

  13. Content type: Case report

    Cholangiocarcinoma is an aggressive tumor with poor prognosis. Most of the cases are not available for surgery at the stage of the diagnosis and the best clinical practice chemotherapy results in about 12-mont...

    Authors: Elena V. Poddubskaya, Madina P. Baranova, Daria O. Allina, Philipp Y. Smirnov, Eugene A. Albert, Alexey P. Kirilchev, Alexey A. Aleshin, Marina I. Sekacheva and Maria V. Suntsova

    Citation: Experimental Hematology & Oncology 2018 7:21

    Published on:

  14. Content type: Case report

    Lapatinib is a tyrosine kinase inhibitor that blocks the HER2 receptor and is typically used in the setting of metastatic breast cancer. Both ERBB2 (HER2) and ERBB3 (HER3) belong to the same family of receptor...

    Authors: John D. Strickley, Aaron C. Spalding, M. Tye Haeberle, Timothy Brown, Don A. Stevens and Jae Jung

    Citation: Experimental Hematology & Oncology 2018 7:20

    Published on:

  15. Content type: Research

    The positive association of multiple myeloma (MM) risk with HLA-C loci C*07:02 g and C*02:02 g, and the negative association of that with C*05:01 g were statistically significant in Whites have recently been r...

    Authors: Xiaojing Wang, Gang An, Jiying Wang, Yan Zhang, Qinghua Li, Hui wei, Lugui Qiu and Kun Ru

    Citation: Experimental Hematology & Oncology 2018 7:19

    Published on:

  16. Content type: Research

    The objective of this randomized placebo-controlled study was to investigate the efficacy and safety of clarithromycin in combination with bortezomib–cyclophosphamide–dexamethasone (VCD) in patients with newly...

    Authors: Henrik Gregersen, Trung Do, Ida Bruun Kristensen, Ulf Christian Frølund, Niels Frost Andersen, Lene Kongsgaard Nielsen, Christen Lykkegaard Andersen, Tobias Wirenfeldt Klausen, Annette Juul Vangsted and Niels Abildgaard

    Citation: Experimental Hematology & Oncology 2018 7:18

    Published on:

  17. Content type: Review

    Prognosis is very poor for advanced HCC patients partially due to lack of effective systemic treatment. Sorafenib was the only approved agent for advanced HCC since 2007 until recent breakthroughs. In this art...

    Authors: Sowmini Medavaram and Yue Zhang

    Citation: Experimental Hematology & Oncology 2018 7:17

    Published on:

  18. Content type: Research

    Patients with polycythemia vera (PV) have a higher mortality risk compared with the general population, primarily driven by cardiovascular disease, thrombotic events (TEs), and hematologic transformations. The...

    Authors: Dilan Paranagama, Philomena Colucci, Kristin A. Evans, Machaon Bonafede and Shreekant Parasuraman

    Citation: Experimental Hematology & Oncology 2018 7:16

    Published on:

  19. Content type: Review

    Bullous hemorrhagic dermatosis (BHD) is a systemic side-effect of low molecular weight heparin, characterized by multiple intra-epidermal hemorrhages distant from the site of injection. There have been several...

    Authors: Armand Russo, Susanna Curtis, Raisa Balbuena-Merle, Roxanne Wadia, Ellice Wong and Herta H. Chao

    Citation: Experimental Hematology & Oncology 2018 7:15

    Published on:

  20. Content type: Case report

    Bone marrow transplant-associated thrombotic microangiopathy (TA-TMA) is a relatively frequent but under-recognized and under-treated hematopoietic stem cell transplant (HSCT) complication that leads to signif...

    Authors: Eric Wirtschafter, Christine VanBeek and Yuliya Linhares

    Citation: Experimental Hematology & Oncology 2018 7:14

    Published on:

  21. Content type: Research

    Aging is associated with complex molecular alterations at the cellular level. Bone marrow exhibits distinct phenotypic, genetic and epigenetic alterations with aging. Metabolic changes in the bone marrow relat...

    Authors: Kwasi M. Connor, Young Hsu, Pardeep Kumar Aggarwal, Stephen Capone, Anthony R. Colombo and Giridharan Ramsingh

    Citation: Experimental Hematology & Oncology 2018 7:13

    Published on:

  22. Content type: Research

    The current standard of care for classical Hodgkin lymphoma (HL) is multiagent chemotherapy with or without radiation. In patients who relapse or fail to respond, additional high-dose chemotherapy with autolog...

    Authors: Patrick B. Johnston, Lauren C. Pinter-Brown, Ghulam Warsi, Kristen White and Radhakrishnan Ramchandren

    Citation: Experimental Hematology & Oncology 2018 7:12

    Published on:

  23. Content type: Case report

    Nivolumab is an immune checkpoint inhibitor targeting programmed death-1 protein and has been approved for the treatment of multiple advanced malignancies. Adverse effects of immune checkpoint inhibitors are d...

    Authors: Shagufta Shaheen, Hamid Mirshahidi, Gayathri Nagaraj and Chung-Tsen Hsueh

    Citation: Experimental Hematology & Oncology 2018 7:11

    Published on:

  24. Content type: Rapid communication

    Prostate cancer is a major health problem worldwide due to its high incidence morbidity and mortality. There is currently a need of improved biomarkers, capable to distinguish mild versus aggressive forms of t...

    Authors: Rafael Sebastián Fort, Cecilia Mathó, Carolina Oliveira-Rizzo, Beatriz Garat, José Roberto Sotelo-Silveira and María Ana Duhagon

    Citation: Experimental Hematology & Oncology 2018 7:10

    Published on:

  25. Content type: Research

    To investigate the exposure-toxicity relationship of bosutinib and to identify the target trough plasma concentration (C0).

    Authors: Akiko Mita, Maiko Abumiya, Masatomo Miura, Takenori Niioka, Saori Takahashi, Tomoko Yoshioka, Yoshihiro Kameoka and Naoto Takahashi

    Citation: Experimental Hematology & Oncology 2018 7:9

    Published on:

  26. Content type: Research

    Phosphatase of regenerating liver-3 (PRL-3) is implicated in oncogenesis of hematological and solid cancers. PRL-3 expression increases metastatic potential, invasiveness and is associated with poor prognosis....

    Authors: Magnus Aassved Hjort, Håkon Hov, Pegah Abdollahi, Esten Nymoen Vandsemb, Unn-Merete Fagerli, Bendik Lund, Tobias Schmidt Slørdahl, Magne Børset and Torstein Baade Rø

    Citation: Experimental Hematology & Oncology 2018 7:8

    Published on:

  27. Content type: Case report

    Acquired primary chromosomal changes in cancer are sometimes found as sole karyotypic abnormalities. They are specifically associated with particular types of neoplasia, essential in establishing the neoplasm,...

    Authors: Ioannis Panagopoulos, Ludmila Gorunova, Hege Kilen Andersen, Astrid Bergrem, Anders Dahm, Kristin Andersen, Francesca Micci and Sverre Heim

    Citation: Experimental Hematology & Oncology 2018 7:7

    Published on:

  28. Content type: Case report

    Immune checkpoint blockade (ICB) is becoming an increasingly prevalent strategy in the clinical realm of cancer therapeutics. With more patients being administered ICB for a host of tumor types, the scope of a...

    Authors: D. E. Meyers, W. F. Hill, A. Suo, V. Jimenez-Zepeda, T. Cheng and N. A. Nixon

    Citation: Experimental Hematology & Oncology 2018 7:6

    Published on:

  29. Content type: Rapid communication

    Expression of SRY [sex-determining region Y]-box11 (SOX11) is specific to mantle cell lymphoma (MCL) and contributes, in conjunction with immunoglobulin variable heavy chain gene mutation status, to the identi...

    Authors: Julien Magne, Alizée Jenvrin, Adrien Chauchet, Olivier Casasnovas, Anne Donzel, Laurence Jego, Bernard Aral, Julien Guy, Nathalie Nadal, Dewi Vernerey, Patrick Callier, Francine Garnache-Ottou and Christophe Ferrand

    Citation: Experimental Hematology & Oncology 2018 7:5

    Published on:

  31. Content type: Case report

    Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immunomodulatory mechanisms of action, demonstrated clinical benefit as monotherapy or in combination with established regimens in pat...

    Authors: Saad Z. Usmani, Imran Khan, Christopher Chiu, David Foureau, Lawrence J. Druhan, Katherine Rigby, Tineke Casneuf and A. Kate Sasser

    Citation: Experimental Hematology & Oncology 2018 7:3

    Published on:

  32. Content type: Case report

    Currently, there are no data available on the best choice of treatment in heavily pretreated patients with advanced breast cancer. However, the combination of oral vinorelbine and capecitabine has been demonst...

    Authors: V. Sgroi, M. Bassanelli, M. Roberto, E. Iannicelli, R. Porrini, P. Pellegrini, A. Tafuri and P. Marchetti

    Citation: Experimental Hematology & Oncology 2018 7:2

    Published on:

  33. Content type: Research

    The optimal strategy for vaccination to induce CD8+ T cell responses against WT1 is not known.

    Authors: Hongtao Liu, Yuanyuan Zha, Noura Choudhury, Gregory Malnassy, Noreen Fulton, Margaret Green, Jae-Hyun Park, Yusuke Nakamura, Richard A. Larson, Andres M. Salazar, Olatoyosi Odenike, Thomas F. Gajewski and Wendy Stock

    Citation: Experimental Hematology & Oncology 2018 7:1

    Published on:

  34. Content type: Case report

    Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreact...

    Authors: Mauricio Sarmiento Maldonado, Pablo Ramírez Villanueva, Pablo Bertín Cortes-Monroy, Veronica Jara Arias, Katherine Soto Donoso, Pablo Uribe Gonzalez, Mauricio Ocqueteau Tachini and Jose Antonio Perez-Simón

    Citation: Experimental Hematology & Oncology 2017 6:32

    Published on:

  35. Content type: Review

    HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HE...

    Authors: Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li and Kongming Wu

    Citation: Experimental Hematology & Oncology 2017 6:31

    Published on:

  36. Content type: Research

    Pegylated interferon alfa-2a (PEG-IFN-α-2a) is a potent immunomodulating agent capable of inducing high rate of hematologic and even complete molecular remission in patients with essential thrombocythemia (ET)...

    Authors: Lucia Masarova, C. Cameron Yin, Jorge E. Cortes, Marina Konopleva, Gautam Borthakur, Kate J. Newberry, Hagop M. Kantarjian, Carlos E. Bueso-Ramos and Srdan Verstovsek

    Citation: Experimental Hematology & Oncology 2017 6:30

    Published on:

  37. Content type: Case report

    The treatment algorithm for metastatic non-small cell lung cancers (NSCLCs) has been evolving rapidly due to the development of new therapeutic agents. Although guidelines are provided by National Comprehensiv...

    Authors: Shuyu D. Li, Annia Martial, Alexa B. Schrock and Jane J. Liu

    Citation: Experimental Hematology & Oncology 2017 6:29

    Published on:

  39. Content type: Research

    Carfilzomib is approved in the United States and Europe for treatment of relapsed or refractory multiple myeloma (MM). This study evaluated pharmacokinetics (PK) and safety of carfilzomib in patients with rela...

    Authors: Jennifer Brown, Ruth Plummer, Todd M. Bauer, Stephen Anthony, John Sarantopoulos, Filip De Vos, Mike White, Marco Schupp, Ying Ou and Ulka Vaishampayan

    Citation: Experimental Hematology & Oncology 2017 6:27

    Published on:

  40. Content type: Research

    Post-transplant lymphoproliferative disorder is a well-recognized but rare complication of hematopoietic stem cell and solid organ transplant. Due to rarity of this disease, retrospective studies from major tr...

    Authors: Rohit Bishnoi, Ravneet Bajwa, Aaron J. Franke, William Paul Skelton IV, Yu Wang, Niraj M. Patel, William Birdsall Slayton, Fei Zou and Nam H. Dang

    Citation: Experimental Hematology & Oncology 2017 6:26

    Published on:

  42. Content type: Review

    Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been considered as a valuable approach in treatment of numerous malignant and none malignant hematologic disorders. However, relapse and poor ...

    Authors: Saeed Mohammadi, Amir Hossein Norooznezhad, Ashraf Malek Mohammadi, Hajar Nasiri, Mohsen Nikbakht, Najmaldin Saki, Mohammad Vaezi, Kamran Alimoghaddam and Ardeshir Ghavamzadeh

    Citation: Experimental Hematology & Oncology 2017 6:24

    Published on:

  44. Content type: Short report

    Traditional two-dimensional (2-D) monolayer cell culture is vastly different from in vivo physiological conditions, which can lead to inaccurate or insufficient data in areas where response and efficacy within...

    Authors: Jiaojiao Zhou, Jimmy Su, Xiaotong Fu, Lei Zheng and Zhizhong Yin

    Citation: Experimental Hematology & Oncology 2017 6:22

    Published on:

  45. Content type: Review

    B cell lymphoma and multiple myeloma (MM) are the most common hematological malignancies which benefit from therapeutic monoclonal antibodies (mAbs)-based immunotherapies. Despite significant improvement on pa...

    Authors: Li Zhang, Yu-Tzu Tai, Matthew Zhi Guang Ho, Lugui Qiu and Kenneth C. Anderson

    Citation: Experimental Hematology & Oncology 2017 6:20

    Published on:

  46. Content type: Case report

    Heparin-induced thrombocytopenia (HIT) is a life and limb-threatening condition caused by the binding of platelet-activating antibodies (IgG) to multimolecular platelet factor 4 (PF4)/heparin complexes because...

    Authors: Daniel E. Ezekwudo, Rebecca Chacko, Bolanle Gbadamosi, Syeda Batool, Sussana Gaikazian, Theodore E. Warkentin, Jo-Ann I. Sheppard and Ishmael Jaiyesimi

    Citation: Experimental Hematology & Oncology 2017 6:21

    Published on:

  48. Content type: Research

    Inflammation is a major feature of sickle cell disease (SCD). Low-dose methotrexate (MTX) has long been used in chronic inflammatory diseases. This pilot study examined the MTX effect on acute vaso-occlusive p...

    Authors: Silvia R. Brandalise, Rosemary Assis, Angelo B. A. Laranjeira, José Andrés Yunes and Pedro O. de Campos-Lima

    Citation: Experimental Hematology & Oncology 2017 6:18

    Published on:

  49. Content type: Review

    Cullin 4B (CUL4B) is a scaffold of the Cullin4B-Ring E3 ligase complex (CRL4B) that plays an important role in proteolysis and is implicated in tumorigenesis. Aberrant expression of CUL4B has been reported in ...

    Authors: Ying Li and Xin Wang

    Citation: Experimental Hematology & Oncology 2017 6:17

    Published on:

  50. Content type: Research

    Multiple myeloma (MM) is a type of hematological malignancy with significant heterogeneity in clinical features and prognosis. Cytogenetic abnormalities are the major factors affecting patient outcomes. Studie...

    Authors: GuoQing Wei, LiJun Wang, HanJin Yang, XiaoYan Han, GaoFeng Zheng, WeiYan Zheng, Jie Sun, JiMin Shi, WenJun Wu, Yi Zhao, DongHua He, Bo Wang, Zhen Cai and JingSong He

    Citation: Experimental Hematology & Oncology 2017 6:16

    Published on:

Submit a manuscript

2017 Journal Metrics

Advertisement

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us